Penumbra, Inc. reported a 6.9% increase in revenue for the first quarter of 2020, reaching $137.3 million. The growth was primarily driven by vascular products, while neuro products experienced a slight decline. Operating income decreased compared to the previous year.
Total revenue grew to $137.3 million, a 6.9% increase over Q1 2019.
Vascular product revenue increased by 26.2%.
Neuro product revenue declined by 4.2%.
Operating income decreased to $0.6 million, compared to $11.2 million in Q1 2019.
Due to the uncertain scope and duration of the pandemic, and uncertain timing of global recovery and economic normalization, Penumbra cannot, at this time, reliably estimate the future impact on our operations and financial results.
Visualization of income flow from segment revenue to net income